Antiangiogenic blockage: A new treatment for glioblastoma

Expert Opinion on Biological Therapy

Volumn 8, Issue 10, 2008, Pages 1449-1453

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiangiogenic therapy; Glioblastoma; High grade glioma

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; IRINOTECAN; TEMOZOLOMIDE;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; EPISTAXIS; GLIOBLASTOMA; HUMAN; HYPERTENSION; INTRATUMORAL BLEEDING; MONOTHERAPY; ORAL BLEEDING; PROTEINURIA; SURVIVAL TIME; TUMOR BLEEDING; VAGINA BLEEDING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54349111868     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.10.1449     Document Type: Editorial

References (19)

1. Reardon DA, Wen PY, Desjardins A, et al. Glioblastoma multiforme: an emerging paradigm for anti-VEGF therapy. Expert Opin Biol Ther 2008;8(4):541-53
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8
3. Stupp R, Mason WP, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant remozolomide for glioblastoma. N Engl J Med 2005;352:987-96
4. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66(8):1258-60
5. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9
6. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
7. Chen C, Silverman DHS, Geist C, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25(30):4714-21
8. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology 2008;70:779-87
9. Cloughsey TF, Prados MD, Mikkelsen T, et al. A phase II randomized non-comparative trial of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma. J Clin Oncol 2008;26(15S):91s
10. Batchelor TT, Sorensen AG, diTomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
11. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82
12. Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
13. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36
14. Batchelor TT, Gilbert M, Supko JG, et al. Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol 2004;6:21-7
15. Prados MD, Lamborn K, Yung WKA, et al. A phase II trail of irinotecan (CPT-11) in patients with recurrent malignant glioma: a NABTC study. Neuro Oncol 2006;8(2):189-93
16. Kerbel R, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20(1-2):79-86
17. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14
18. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24(20):3293-8
19. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol 2005;7(3):369